New options in the treatment of lipid disorders in HIV-infected patients

Open AIDS Journal

Volumn 3, Issue , 2009, Pages 31-37

  Da Silva, Erika Ferrari Rafael ^a   Bárbaro, Giuseppe ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acquired immunodeficiency syndrome; Dyslipidemia; Ezetimibe; Fish oil; Highly active antiretroviral therapy; Human immunodefciency virus; Statins

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; LIPID; LOPINAVIR PLUS RITONAVIR; MEVINOLIN; OMEGA 3 FATTY ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DYSLIPIDEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; PRIORITY JOURNAL; REVIEW;

EID: 75149113123     PISSN: None     EISSN: 18746136     Source Type: Journal    
DOI: 10.2174/1874613600903010031     Document Type: Review

References (55)

1. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIVinfected patients: a prospective study in 95 patients. Eur J Clin Invest 1994; 24(6): 416-420 (Pubitemid 24201271)
2. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferonalpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991; 90(2): 154-162
3. Shor-Posner G, Basit A, Lu Y, et al. Hypocholesterolaemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993; 94(5): 515-519 (Pubitemid 23142967)
4. Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr 2000; 25 (Suppl 1): S4-11.
5. Distler O, Cooper DA, Deckelbaum RJ, Sturley SL. Hyperlipidemia and inhibitors of HIV protease. Curr Opin Clin Nutr Metab Care 2001; 4(2): 99-103.
6. Barbaro G. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5(4): 337-343 (Pubitemid 41135805)
7. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860 (Pubitemid 28135961)
8. Manfredi R. Management of dyslipidemia in patients with HIV disease. Clin Microbiol Infect 2000; 6(11): 579-584 (Pubitemid 34966073)
9. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283(3): 381-390 (Pubitemid 30051757)
10. Currier JS. How to manage metabolic complications of HIV therapy: what to do while we wait for answers. AIDS Read 2000; 10 (3): 162-169
11. Klein D, Hurley LB, Quesenberry CP, Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30(5): 471-477
12. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Clinical Epidemiology Group from the French Hospital Database. Increased risk for myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486
13. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58. (Pubitemid 28190689)
14. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351 (9119): 1881-1883 (Pubitemid 28279721)
15. Fauvel J, Bonnet E, Ruidavets JB, et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001; 15 (18): 2397-2406 (Pubitemid 34014608)
16. Bonnet E, Ruidavets JB, Tuech J, et al. Apoprotein c-III and Econtaining lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endocrinol Metab 2001; 86 (1): 296-302. (Pubitemid 32109809)
17. Caron M, Auclair M, Sterlingot H, Kornprobst M, Capeau J. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003; 17(17): 2437-2444
18. Jones SP, Janneh O, Back DJ, Primohammed M. Altered adipocytokines gene expression in murine 3T3-F442A adipocyte treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther 2003; 8: 1-11.
19. Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluationa and management of dyslipidemia in human immunodeficiency vírus (HIV) - Infected Adutls Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37: 613-627
20. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002; 106: 3143-3221
21. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16(4): 569-577
22. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003; 17(6): 851-859 (Pubitemid 36547657)
23. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006; 97(8A): 27C-31C.
24. Williams B, Feely J. Pharmacokinetic-pharmacodynamic drug in interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 434-470 (Pubitemid 34713089)
25. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003; 25(11): 2822-2835 (Pubitemid 37510592)
26. Cheng JW. Rosuvastatin in the management of hyperlipidemia. Clin Ther 2004; 26(9): 1368-1387
27. Bottaro EG, Caravello O, Scapellato PG, et al. Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Enferm Infecc Microbiol Clin 2008; 26(6): 325-329 (Pubitemid 351879842)
28. Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res 2008; 6(6): 572-578
29. Van der Lee M, Sankatsing R, Schippers E, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther 2007; 12(7): 1127-1132 (Pubitemid 350114993)
30. Merck/Schering-Plough Pharmaceuticals. Zetia (ezetimibe) product information. North Wales, PA, 2005.
31. Negredo E, Molto J, Puig J, et al. Ezetimibe, a promising lipidlowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 2006; 20(17): 2159-2164 (Pubitemid 44684706)
32. Gagné C, Bays HE, Weiss SR, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90 (10):1084-1091 (Pubitemid 35339435)
33. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005; 80(5): 587-595 (Pubitemid 40628813)
34. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005; 44 (5): 467-494 (Pubitemid 40733733)
35. Stein E, Stender S, Mata P, et al. Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe coadministered with atorvastatin. Am Heart J 2004; 148(3): 447-455
36. Farnier M, Freeman MW, Macdonell G, et al. The Ezetimibe Study Group. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005; 26(9): 897-905.
37. Coll B, Aragonés G, Parra S, Alonso-Villaverde C, Masana L. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 2006; 20(12): 1675-1677 (Pubitemid 44162414)
38. Bennett MT, Johns KW, Bondy GP. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis 2007; 6: 15.
39. Stebbing J, Asghar AK, Holmes P, Bower M, Isenman HL, Nelson M. Use of ezetimibe during HIV infection. J Antimicrob Chemother 2009; 63(1): 218-220
40. Berg-Wolf MV, Klibanov OM, Gaughan JP, Tedaldi EM. Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS Patient Care STDS 2008; 22(6): 483-488
41. Simons LA, Hickie JB, Balasubramaniam S. On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia. Atherosclerosis 1985; 54(1): 75-88. (Pubitemid 15174345)
42. Bang HO, Dyerberg J, Hjøorne N. The composition of food consumed by Greenland Eskimos. Acta Med Scand 1976; 200(1-2): 69-73.
43. Weber P, Raederstorff D. Triglyceride-lowering effect of omega-3 LC-polyunsaturated fatty acids - a review. Nutr Metab Cardiovasc Dis 2000; 10(1): 28-37.
44. O'Keefe JH Jr, Harris WS. From Inuit to implementation: omega-3 fatty acids come of age. Mayo Clin Proc 2000; 75(6): 607-614 (Pubitemid 30395923)
45. Harris WS, Connor WE, McMurry MP. The comparative reductions of the plasma lipids and lipoproteins by dietary polyunsaturated fats: salmon oil versus vegetable oils. Metabolism 1983; 32(2): 179-184
46. Stone NJ. Fish consumption, fish oil, lipids, and coronary heart disease. Circulation 1996; 94(9): 2337-2340 (Pubitemid 26360549)
47. Perez CF, Perales J, Fraile G. The hypolipemic effect of concentrated salmon oil rich in n-3 fatty acids. An Med Interna 1990; 7: 299-303.
48. Kris-Etherton PM, Harris WS, Appel LJ. American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106 (21): 2747-2757 (Pubitemid 35364932)
49. Manfredi R, Calza L, Chiodo F. Polyunsaturated ethyl esters of n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy. J Acquir Immune Defic Syndr 2004; 36 (3): 878-880 (Pubitemid 38859356)
50. Wohl DA, Tien HC, Busby M, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis 2005; 41(10): 1498-1504 (Pubitemid 41579995)
51. Carter VM, Woolley I, Jolley D, Nyulasi I, Mijch A, Dart A. A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy. Sex Health 2006; 3: 287-290 (Pubitemid 44777065)
52. De Truchis P, Kirstetter M, Perier A, et al. Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIVinfected patients taking potent antiretroviral therapy: a randomized prospective study. J Acquir Immune Defic Syndr 2007; 44(3): 278-285 (Pubitemid 46328343)
53. Calza L, Manfredi R, Pocaterra D, Chiodo F. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy. J Infect 2008; 57(1): 16-32.
54. Soler A, Deig E, Guil J, Rodríguez-Martín M, Guelar A, Pedrol E. Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia. Med Clin (Barc) 2006; 127(7): 250-252 (Pubitemid 44343356)
55. Bader MS, Kelly DV. Diagnosis and management of common chronic metabolic complications in HIV-infected patients. Postgrad Med 2008; 120(4): 1-11.